CGRP inhibitors, established as safe and effective for adult migraine, may be appropriate for pediatric patients in certain clinical situations despite limited studies in this population.
Limited pediatric evidenceDespite established adult safety and efficacy, there are few well-studied treatments for pediatric migraine, and CGRP inhibitor data in children remains limited
What the researchers found
CGRP inhibitors are established as safe and effective for adult migraine treatment, and their use may be appropriate for pediatric patients in certain clinical situations. The review describes migraine pathophysiology as it relates to CGRP, provides an overview of available CGRP-targeting medications (both monoclonal antibodies and small-molecule antagonists), and discusses clinical usage considerations for children and adolescents. The limited evidence base for this population is a key theme.
Why it matters
Migraine is one of the most common neurological conditions in children, yet treatment options are severely limited. CGRP inhibitors have transformed adult migraine care, and many pediatric neurologists are already using them off-label for younger patients. This review provides a framework for evidence-based decision-making about when and how to use these peptide-targeted therapies in children.
How the study worked
Narrative literature review examining CGRP migraine pathophysiology, available CGRP inhibitor medications, and their clinical usage in pediatric and adolescent populations. Published in Pediatric Neurology.
What this study cannot tell us
This is a narrative review, not a systematic review. The fundamental limitation is the lack of large randomized controlled trials of CGRP inhibitors specifically in pediatric populations. Most evidence is extrapolated from adult trials, with limited pediatric case series and off-label use data. Long-term safety in growing children is unknown. The review acknowledges that current evidence for pediatric use is limited.
How to read the evidence
This is a narrative review published in Pediatric Neurology, a respected specialty journal. The review synthesizes available evidence but highlights the fundamental gap — lack of large pediatric RCTs for CGRP inhibitors.
When this study was published
Published in 2024, this is a current review capturing the latest thinking on CGRP inhibitors in pediatric migraine as the field awaits more pediatric-specific clinical trial data.
The bigger picture
CGRP-targeting therapies represent the first mechanism-specific treatments for migraine, based on decades of research into the peptide's role in pain signaling. As these drugs expand from adults to children, understanding their safety profile in developing brains and bodies is critical. Pediatric migraine is a significant burden on children's quality of life and education, making effective treatments particularly important.
Questions still open
- Will ongoing pediatric clinical trials of CGRP inhibitors confirm safety and efficacy profiles similar to adults?
- Are there developmental considerations for blocking CGRP in children, given the peptide's roles beyond migraine?
- Which pediatric migraine patients are the best candidates for CGRP inhibitors as an alternative to traditional preventive therapies?
Common questions
Are CGRP inhibitors approved for children with migraines?
How does CGRP cause migraines in children?
Read the original research
Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Migraine in the Pediatric and Adolescent Populations: A Review.
Pediatric neurology, 157, 87-95
Citation
Moore, Lisa; Pakalnis, Ann. (2024). Calcitonin Gene-Related Peptide Inhibitors in the Treatment of Migraine in the Pediatric and Adolescent Populations: A Review.. Pediatric neurology, 157, 87-95. https://doi.org/10.1016/j.pediatrneurol.2024.05.013